An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Wen Y, Gamazon ER, Bleibel WK, Wing C, Mi S, McIlwee BE, Delaney SM, Duan S, Im HK, Dolan ME (2012) Hum Mol Genet 21: 1470-80 Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH (2012) Cancer 118: 1007-13 Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML (2008) Invest New Drugs 26: 339-45 Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Gamazon ER, Trendowski MR, Wen Y, Wing C, Delaney SM, Huh W, Wong S, Cox NJ, Dolan ME (2018) Sci Rep 8: 733
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.